Combination of Etanercept and Twice-Weekly Administration of Cyclosporin in Psoriasis Unsatisfactorily Controlled by Etanercept Monotherapy: A Retrospective Analysis
Free accessLetterFirst published online August, 2012
Combination of Etanercept and Twice-Weekly Administration of Cyclosporin in Psoriasis Unsatisfactorily Controlled by Etanercept Monotherapy: A Retrospective Analysis
Combination of systemic biological and traditional agents is increasingly used for the treatment of “high-need” patients with psoriasis. There are only limited data on the combination of cyclosporine (CsA) with biologicals. We report our experience concerning the use of etanercept in combination with CsA, given at a dose of 3–5mg/kg two days per week, in patients with insufficient response of psoriasisto etanercept monotherapy. The retrospective analysis of 17 patients showed that the addition of CsA for 2–8 months was capable of inducing a relevant clinical benefit in a total of 12 patients. The combination treatment was tolerated by all patients except one who had to stop CsA treatment because of repeated hypertensive crises.
WarrenRB, BrownBC, LaveryD, AshcroftDM, GriffithsCE. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol2009; 160:162–9.
2.
DriessenRJB, BoezemanJB, van de KerkhofPCM, de JongEM. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol2009; 160:670–5.
3.
AltomareG, AyalaF, BerardescaE, Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol Ther2008; 21(S):S1–14.
4.
BachmannF, KokolakisG, SterryW, PhilippS. Etanercept: overview of clinical experience in the treatment of psoriasis and psoriatic arthritis. Int J Clin Rheumatol2011; 6:135–55.
5.
van de KerkhofPCM, SegaertS, LahfaM, Once weekly administration of etanercept 5,0 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol2008; 159:1177–85.
6.
FoleyPA, QuirkC, SullivanJR, Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. J Eur Acad Dermatol Venereol2010; 24:1135–43.
LeeEJ, ShinMK, KimNI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol2010; 22:138–42.
9.
AtzeniF, BoccassiniL, AntivalleM, SalaffiF, Sarzi-PuttiniP. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomized pilot study. Ann Rheum Dis2011; 70:712–4.
10.
D'AngeloS, CutroMS, LubranoE, Combination therapy with Ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis2010; 69:934–5.
11.
IoannidesD, Mattheou-VakaliG, LazaridouE, BatsiosK, PanagiotidouD, MinasA. Maintenance treatment with cyclosporin in psoriasis. Br J Dermatol1997; 136:470–1.
12.
ThaçiD., BräutigamM, KaufmannR, WeidingerG, PaulC, ChristophersE. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomized study. Dermatology2002; 205:383–8.
13.
VenaGA, CassanoN, GalluccioA, Evaluation of the efficacy and tolerability of a new intermittent treatment regimen with cyclosporin A in severe psoriasis. G Ital Dermatol Venereol2005; 140:575–82.
14.
ColomboD, CassanoN, AltomareG, GiannettiA, VenaGA. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study. Int J Immunopathol Pharmacol2010; 23:1143–52.
